The world’s pharmaceutical industry continued its trend of consolidation Thursday as Sweden-based drug company Meda announced plans to acquire Italy’s Rottapharm for $3.1 billion.
Reports say the takeover marks the largest merger ever struck in Media’s history.
The pharmaceutical giant had earlier said that it prefers “to eat and not be eaten” in a global market that has seen a wave of M&A activity in recent months. According to reports, Meda has turned down a takeover offer by Mylan, based in the US.
Some industry experts had hoped Mylan would up its bid for the deal, but those hopes were dashed when Mylan acquired a portfolio from rival Abbott earlier last month.
Meda and Rottapharm expect to finalize the deal in the fourth quarter.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
